Panacea Biotec Receives ₹45.71 Crore Income Tax Demand Order
Panacea Biotec received a ₹45.71 Crore income tax demand order for Assessment Year 2015-16 due to disallowed expenditures. The company disputes the demand, citing revised tax filings showing no tax liability. Legal recourse, including an appeal, is being pursued, with no significant financial impact anticipated.
While the company disputes the demand and does not foresee a significant impact, a tax demand of ₹45.71 Crore can potentially affect financial operations if not resolved favorably.
The company has received a significant tax demand order, which is a negative development.
Panacea Biotec Limited announced on March 02, 2026, that it has received a Demand Order dated February 27, 2026, from the Office of the Deputy Commissioner of Income Tax, Central Circle 29, Delhi. The order, issued under Section 156 of the Income Tax Act, 1961, imposes a demand aggregating to ₹45.71 Crore.
This demand arises from the disallowance of certain expenditures related to the Assessment Year 2015-16. The Assessing Officer disallowed deductions under Section 37 of the Income Tax Act due to incorrect categorization of certain expenses, which were deemed in violation of Medical Council of India (MCI) Regulations.
The company received this order on March 01, 2026. Panacea Biotec assesses the demand as non-maintainable, stating that it fails to account for revised tax filings which show no taxable income or tax liability due to brought-forward losses. The company is pursuing all necessary legal recourse, including filing a rectification application and an appeal before the relevant appellate authority. Panacea Biotec does not foresee any significant impact on its financial, operational, or other activities.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.